Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
SAN FRANCISCO, Feb. 01, 2017 -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced that it will release financial results for the fourth quarter and 2016 after the close of trading on Wednesday, February 15, 2017. The company’s management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.
Investors interested in listening to the conference call may do so by dialing (844) 348-0016 for domestic callers or (213) 358-0876 for international callers, using Conference ID: 58707805. A live and archived webcast of the event will be available on the “Investor Relations” section of the company’s website at: www.irhythmtech.com.
About iRhythm Technologies, Inc.
iRhythm is a commercial-stage digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients. The company’s platform, the Zio Service, has been provided to over 600,000 patients, accumulating more than 150 million hours of curated heartbeat data within iRhythm’s data repository.
Investor Relations Contact: Lynn Pieper Lewis or Leigh Salvo (415) 937-5404 [email protected] Media Contact Aaron Murphy (415) 229-3331 [email protected]
